Elevated serum circulating cell‐free mitochondrial DNA in amyotrophic lateral sclerosis

Jieyu Li,Chao Gao,Qingqing Wang,Jing Liu,Zhiying Xie,Yawen Zhao,Meng Yu,Yiming Zheng,He Lv,Wei Zhang,Yun Yuan,Lingchao Meng,Jianwen Deng,Zhaoxia Wang
DOI: https://doi.org/10.1111/ene.16493
2024-09-28
European Journal of Neurology
Abstract:Background and Purpose The substantial role of inflammation in amyotrophic lateral sclerosis (ALS) is gaining support from recent research. Studies indicate that circulating cell‐free mitochondrial DNA (ccf‐mtDNA) can activate the immune system and is associated with neurodegenerative diseases. This research was designed to quantify ccf‐mtDNA levels in the serum of ALS patients. Methods The medical records of ALS patients were reviewed. Serum ccf‐mtDNA levels of patients with ALS (n = 62) and age‐matched healthy controls (n = 46) were measured and compared. Additionally, serum interleukin‐6 (IL‐6) levels were measured using an enzyme‐linked immunosorbent assay in 26 ALS patients. Correlations between variables were analyzed. Results Serum ccf‐mtDNA was notably higher in the patients with ALS. When stratified by genotype, the superoxide dismutase 1 (SOD1) mutation group showed the greatest increase in ccf‐mtDNA levels relative to other ALS patients. Among all 108 individuals, a cut‐off set at 1.1 × 105 mtDNA copies on a receiver‐operating characteristic curve identified patients with ALS with 80.7% sensitivity and 50.0% specificity; the area under the curve was 0.69 (p
neurosciences,clinical neurology
What problem does this paper attempt to address?